BioMarin Pharma (BMRN): Utang-utang marang kapitalisasi buku

BioMarin Pharmaceutical (BMRN) relies on monopoly pricing within the orphan drug segment. High barriers to entry and government privileges ensure profit protection, which is confirmed by the current debt-to-book capitalization ratio. Revolutionary gene therapy methods guarantee margin growth. The value of 0.66 serves as the final marker for the company's debt leverage level.

BMRN - Utang-utang marang aset resik BioMarin Corp ing rentang 04.07.2022 - 28.10.2026

Rincian metrik lan analitis perusahaan BioMarin Pharmaceutical Inc. (BMRN)

- rega lan prakiraan konsensus rega:

Rega saham BioMarin Pharmaceutical|BMRN - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Kapitalisasi pasar BioMarin Corp|BMRN - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham BioMarin|BMRN - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku biomarin.com|BMRN - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas BioMarin Pharmaceutical|BMRN - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal BioMarin Pharma|BMRN - Gunggung kewajiban utang perusahaan|Utang marang nilai buku BioMarin Corp

Analisis kabeh metrik perusahaan:BioMarin Pharmaceutical

Produk asli BioMarin Pharmaceutical Inc.

For BioMarin Pharmaceutical (BMRN), which actively invests in breakthrough gene therapies and the expansion of its R&D pipeline, the debt-to-market capitalization financing structure reflects the balance between borrowed capital and the market value of equity. This indicator calculates the ratio of total liabilities to capitalization based on daily quotes, allowing investors to assess the level of financial leverage and the company's ability to attract resources for accelerated development.

Pesaing BioMarin Pharmaceutical